DT
HealthMore in Health→
Early Trial Signals Lower Relapse, Less Severe GVHD After Allogeneic Transplant
Key Takeaways
- Medical Xpress highlighted a Phase I trial result for the VIC-1911 regimen.
- The supplied source text says patients had lower relapse risk and lower rates of graft-versus-host disease.
- The result is early but notable because it appears to improve both safety and disease control at once.
DE
DT Editorial Team··via medicalxpress.com